Community acquired pneumonia incidence before and after proton pump inhibitor prescription: Population based study

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Othman, Fatmah ^a,b   Crooks, Colin J ^a   Card, Timothy R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

CASE CONTROL STUDY; COHORT ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA; PROPORTIONAL HAZARDS MODEL; RISK; TIME FACTOR; UNITED KINGDOM;

CASE-CONTROL STUDIES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RISK; TIME FACTORS; UNITED KINGDOM;

EID: 84996917490     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i5813     Document Type: Article

References (37)

1. Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 2014;32:618-22. doi:10. 1016/j. ajem. 2014. 03. 019.
2. Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 2012;12:408. doi:10. 1186/1472-6963-12-408.
3. Heidelbaugh JJ, Goldberg KLIJ. Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 2009;5:725-34.
4. Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?World J Gastrointest Pharmacol Ther 2011;2:17-26. doi:10. 4292/wjgpt. v2. i3. 17.
5. Eom C-S, Jeon CY, Lim J-W, Cho E-G, Park SM, Lee K-S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310-9. doi:10. 1503/cmaj. 092129.
6. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012;46:93-114. doi:10. 1097/MCG. 0b013e3182333820.
7. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10:e0128004. doi:10. 1371/journal. pone. 0128004.
8. Barkun AN, Bardou M, Pham CQD, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012;107:507-20, quiz 521. doi:10. 1038/ajg. 2011. 474.
9. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008;22:761-6. doi:10. 1155/2008/821385.
10. Millett ER, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One 2013;8:e75131. doi:10. 1371/journal. pone. 0075131.
11. Laheij RJ, Sturkenboom MC, Hassing R-J, Dieleman J, Stricker BHC, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60. doi:10. 1001/jama. 292. 16. 1955.
12. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5. doi:10. 1001/archinte. 167. 9. 950.
13. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009;18:269-75. doi:10. 1002/pds. 1715.
14. Sarkar M, Hennessy S, Yang Y-X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-8. doi:10. 7326/0003-4819-149-6-200809160-00005.
15. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:792-802. doi:10. 1002/pds. 1978.
16. Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012;54:33-42. doi:10. 1093/cid/cir767.
17. Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013;28:223-30. doi:10. 1007/s11606-012-2211-5.
18. Filion KB, Chateau D, Targownik LE, et al. CNODES Investigators. Proton pump inhibitors and the risk of hospitalisation for communityacquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014;63:552-8. doi:10. 1136/gutjnl-2013-304738.
19. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36. doi:10. 1093/ije/dyv098.
20. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9. doi:10. 1592/phco. 23. 5. 686. 32205.
21. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012;3:89-99. doi:10. 1177/2042098611435911.
22. Digital NHS. Hospital Episode Statistics. 2015. http://www. hscic. gov. uk/hes. 23 National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. NICE, 2014.
23. Niederman MS. Understanding the natural history of community-acquired pneumonia resolution: vital information for optimizing duration of therapy. Clin Infect Dis 2004;39:1791-3. doi:10. 1086/426031.
24. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009;18:7-26. doi:10. 1177/0962280208092342.
25. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25:1768-97. doi:10. 1002/sim. 2302.
26. Immunisation against infectious disease, Contraindications and special considerations. InSalisbury D, Ramsay M, eds. The Green Book. Public Health England, 2013: 41-8.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. doi:10. 1016/0021-9681(87)90171-8.
28. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009;338:b81. doi:10. 1136/bmj. b81.
29. Yu M, Xie D, Wang X, Weiner MG, Tannen RL. Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies. Pharmacoepidemiol Drug Saf 2012;21(Suppl 2):60-8. doi:10. 1002/pds. 3235.
30. Uddin MJ, Groenwold RH, van Staa TP, et al. Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf 2015;24:468-77. doi:10. 1002/pds. 3724.
31. Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot J-F. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract 2012;66:767-73. doi:10. 1111/j. 1742-1241. 2012. 02973. x.
32. Christine Bond. The over-the-counter pharmaceutical market policy and practice. Eurohealth (Lond) 2008;14(3).
33. Allison P, Waterman R. Fixed-effects negative binomial regression models. Sociol Methodol 2002;32:247-65doi:10. 1111/1467-9531. 00117.
34. Armstrong BG, Gasparrini A, Tobias A. Conditional Poisson models: a flexible alternative to conditional logistic case cross-over analysis. BMC Med Res Methodol 2014;14:122. doi:10. 1186/1471-2288-14-122.
35. Quint JK, Müllerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open 2014;4:e005540. doi:10. 1136/bmjopen-2014-005540.
36. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31:627-36. doi:10. 2165/00002018-200831070-00008.
37. Estborn L, Joelson S. Frequency and time to onset of communityacquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther 2015;42:607-13. doi:10. 1111/apt. 13304.